Answers are grounded in this paper and cite their sources.
Significance Topoisomerases are crucial for genome maintenance and are targets for several chemotherapeutic agents. While anticancer drugs targeting topoisomerases can lead to secondary malignancies, there have been no descriptions of genetic defects in topoisomerases having roles in cancer development. Here we show that a somatic topoisomerase IIα mutation found in human tumors results in a mutator phenotype. We show that this mutation and the concomitant mutational signature, which we call ID_TOP2α, are associated with genomic rearrangements and with potentially oncogenic indel mutations in known driver genes. Our results shed new light on topoisomerase IIα function, on repair of trapped cleavage complexes, and on a likely oncogenic role for topoisomerases.
No takes yet. Share an insight, caveat, or question.
Boot et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: